Rybelsus
semaglutide — GLP-1 receptor agonist by Novo Nordisk
GLP-1oralOnce dailyFDA Approved
Reviewed by Dr. Elena Vance, DOLast reviewed 2 sources cited
FDA-Approved Indications
- Type 2 diabetes mellitus (adjunct to diet and exercise)
Dosing
| Route | oral |
| Frequency | Once daily |
| Starting Dose | 3 mg daily |
| Maintenance | 7 mg or 14 mg daily |
| Max Dose | 14 mg daily |
| Titration | 3 mg daily x 30 days → 7 mg daily. May increase to 14 mg after 30+ days. Take on empty stomach with ≤4 oz water, 30 min before food. |
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Nausea | 11-20% | 2/5 |
| Abdominal pain | 5-11% | 2/5 |
| Diarrhea | 5-10% | 2/5 |
| Decreased appetite | 3-9% | 1/5 |
| Vomiting | 4-8% | 3/5 |
| Constipation | 3-5% | 1/5 |
| Pancreatitis (rare) | <0.5% | 5/5 |
Cost
| List Price | $935-$1,029/month |
| With Insurance | $25-$150/month (varies by plan) |
| Savings Card | $10/month (Novo Nordisk savings card, commercially insured) |
Pricing last updated 2026-04-14. Actual costs vary by pharmacy, insurance plan, and location.
Compare Rybelsus With
Boxed Warning
Thyroid C-cell tumors: In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether semaglutide causes thyroid C-cell tumors in humans.
Sources
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.